Grouping, Family and System Applications for Devices in Tanzania

1. Key takeaways

Tanzania allows several devices to be placed in a single application, but the precondition for doing so is selecting the correct grouping category first. Compendium Part IX provides 6 grouping categories and 5 determination flowcharts:

New models can be added to a registered family only through a variation application, and must satisfy the permissible variant conditions (§3.3.1); devices under different brand names must be re-submitted as a new product registration application even if they satisfy the family conditions (change guidelines TMDA/DMD/MDA/G/003 §4(h), §4(i)).

2. Legal basis

3. Expert insights

Insight 1: the family conditions form an and-chain, and if a single link breaks the devices fall back to single applications.

The five conditions a–e of §3.1 must be satisfied simultaneously. The official counter-example is telling: for contact lenses, toric and spherical lenses — differing in intended purpose and performance, and in design and manufacture — do not constitute one family. Contact lenses with a UV protection feature, by contrast, can join the family, because the feature does not affect the basic design and manufacture of the lens. Portfolio planners should apply the same logic to their own product lines: a feature that changes the intended purpose or the manufacturing process, however small it looks commercially, breaks the family.

Insight 2: the permissible variants are a closed list, specified product by product.

§3.2 provides a table of permissible variants product by product (catheters: number of lumens, material, curvature, lubricious coating; sutures: number of strands, needles, coils, colouring; stents: delivery system approach, flaring or sleeves, among others) and additionally lists generic variants (colour, diameter/length/width/Gauge, shape/size/volume, sterilisation method, radiopacity, flexibility and the like). Sterile versus non-sterile status is also within the generic variant list — a point frequently overlooked, which in practice can significantly reduce the number of applications. Companies should map their full model range against this table before deciding how many applications to file.

Insight 3: cross-manufacturer components inside a system require both authorisation and compatibility evidence.

The later part of §3.4.1: if a system includes devices or components from another product owner, the registration authorisation of those owners and evidence of compatibility with the system must be submitted. The certificate lists only the principal device manufacturer, but the documentation of the other manufacturers still forms part of the registration submission. Procurement and licensing teams should start collecting these authorisations early, because third-party owners are often slow to issue them.

Insight 4: the IVD cluster is a Tanzania-specific cost-saving channel, but it has two locks.

§3.6: the devices must be of the same risk class (Class A only or Class B only), the same methodology and the same cluster category; the cluster category and methodology correspondence table in §3.6.1 is likewise a closed list (for example, under clinical chemistry: enzyme reagents, substrate reagents and electrolyte reagent categories). The second lock is in the final sentence of §3.6: cluster grouping is for product registration only and may not be used as the grouping basis for adding models through a variation notice. IVD portfolio plans that assume clusters can grow indefinitely through variations will meet this wall at the first model extension.

Insight 5: the value of a group lies in free combination within a closed list.

§3.7: once the group registration is completed, the owner may, within the closed list, change the quantity and permutation of the devices to meet the needs of different hospitals or physicians, as long as the same group name and intended purpose are maintained. §3.7 also gives a counter-example: promotional or convenience packs without a group name and without a common medical purpose do not constitute a group (for example, care solution plus saline plus a lens case), and the devices in such packs must be registered separately as single devices. Marketing teams should route all bundle concepts through this test before launch.

Insight 6: grouping does not change the subject of post-market obligations.

The final paragraph of §2: the MAH must discharge six obligations a–f for all devices and components it registers or notifies, whether individually or grouped: comply with the conditions, apply for changes, keep supply records, keep complaint records, report defects and adverse events to the TMDA, and notify the TMDA of FSCA including recalls. Grouping consolidates paperwork at the front door; it changes nothing about the vigilance and recall duties that follow.

4. Practical recommendations

1. Run the Part IX flowcharts before submission, and write the selection conclusion (category plus the provision relied on) onto the first page of the application.
2. Attach to family applications the declaration of differences in shape, colour, flavour or size (§3.3), checked item by item against the permissible variant list.
3. Attach to system applications the declaration of the function of each component (§3.4.1), and secure authorisation and compatibility data for cross-manufacturer components in parallel.
4. When planning model extension, design the differences as permissible variants first; once beyond the list or under a different brand name, only a new application remains.
5. For IVD lines, evaluate Class A/B clusters first, but write the rule that clusters cannot be used to add models through variations into the internal SOP.

5. Verification checklist

• □ The grouping category (single / family / system / IVD test kit / IVD cluster / group) has been selected and the determination basis recorded.
• □ Family applications have been checked item by item against the closed list of permissible variants.
• □ System applications have secured the authorisation of other product owners and compatibility evidence.
• □ IVD clusters have been confirmed as Class A only or Class B only, same methodology and same category.
• □ Group applications have confirmed a single proprietary group name plus a single packaging unit plus a common intended purpose.
• □ Model extension plans have excluded cases where a different brand name requires a new application (G/003 §4(h), §4(i)).

Regulatory information verified as of 29 October 2026. All content cited in this document has been checked against the official published text of the TMDA (June 2024 Compendium, Part IX §1–§3.8, §3.3.1, §3.4.1, §3.6, §3.6.1, §3.7, §3.7.1 and §3.8, and Part I §3.3.1; change guidelines TMDA/DMD/MDA/G/003 §4); the review is repeated whenever the regulations are updated.

• Tanzania local resources: GRZAN can coordinate licensed local responsible persons (LRP) and distributor resources covering online submission, sample delivery, quality audit support and port clearance.
• Service capabilities: classification determination, registration and notification pathway selection, technical documentation (CSDT/STED) preparation and localization, GMDN and grouping strategy, clinical evidence organization, software and AI device submissions, change management, vigilance and PMS reporting, annual retention fee and renewal management.
• Contact: info@grzanglobal.com.